#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Clinically relevant photodynamic therapy ( PDT ) was introduced about 45 years ago as a novel means for selectively eradicating a variety of solid tumors via cytotoxic photochemistry .
3-1	17-27	Clinically	abstract[4]	new[4]	appos	3-6[0_4]
3-2	28-36	relevant	abstract[4]	new[4]	_	_
3-3	37-49	photodynamic	abstract|abstract[4]	new|new[4]	coref	19-21
3-4	50-57	therapy	abstract[4]	new[4]	_	_
3-5	58-59	(	_	_	_	_
3-6	60-63	PDT	abstract	giv	coref	4-6
3-7	64-65	)	_	_	_	_
3-8	66-69	was	_	_	_	_
3-9	70-80	introduced	_	_	_	_
3-10	81-86	about	time[6]	new[6]	_	_
3-11	87-89	45	time[6]	new[6]	_	_
3-12	90-95	years	time[6]	new[6]	_	_
3-13	96-99	ago	time[6]	new[6]	_	_
3-14	100-102	as	_	_	_	_
3-15	103-104	a	_	_	_	_
3-16	105-110	novel	_	_	_	_
3-17	111-116	means	_	_	_	_
3-18	117-120	for	_	_	_	_
3-19	121-132	selectively	_	_	_	_
3-20	133-144	eradicating	_	_	_	_
3-21	145-146	a	abstract[7]	new[7]	_	_
3-22	147-154	variety	abstract[7]	new[7]	_	_
3-23	155-157	of	abstract[7]	new[7]	_	_
3-24	158-163	solid	abstract[7]|object[8]	new[7]|new[8]	coref	8-16[53_8]
3-25	164-170	tumors	abstract[7]|object[8]	new[7]|new[8]	_	_
3-26	171-174	via	abstract[7]|object[8]	new[7]|new[8]	_	_
3-27	175-184	cytotoxic	abstract[7]|object[8]|abstract|abstract[10]	new[7]|new[8]|new|new[10]	_	_
3-28	185-199	photochemistry	abstract[7]|object[8]|abstract[10]	new[7]|new[8]|new[10]	_	_
3-29	200-201	.	_	_	_	_

#Text=As an anti-tumor modality , PDT is unique in requiring three components : a photosensitizing agent ( PS ) , PS-exciting light in the far-visible-to-near-infrared range , and molecular oxygen .
4-1	202-204	As	_	_	_	_
4-2	205-207	an	abstract[11]	new[11]	_	_
4-3	208-218	anti-tumor	abstract[11]	new[11]	_	_
4-4	219-227	modality	abstract[11]	new[11]	_	_
4-5	228-229	,	_	_	_	_
4-6	230-233	PDT	abstract	giv	coref	5-4
4-7	234-236	is	_	_	_	_
4-8	237-243	unique	_	_	_	_
4-9	244-246	in	_	_	_	_
4-10	247-256	requiring	_	_	_	_
4-11	257-262	three	quantity[13]	new[13]	_	_
4-12	263-273	components	quantity[13]	new[13]	_	_
4-13	274-275	:	_	_	_	_
4-14	276-277	a	person[15]	new[15]	_	_
4-15	278-294	photosensitizing	event|person[15]	new|new[15]	_	_
4-16	295-300	agent	person[15]	new[15]	_	_
4-17	301-302	(	_	_	_	_
4-18	303-305	PS	abstract	new	coref	5-1
4-19	306-307	)	_	_	_	_
4-20	308-309	,	_	_	_	_
4-21	310-321	PS-exciting	event|abstract[18]	new|new[18]	coref|coref	7-33[0_18]|7-33[0_18]
4-22	322-327	light	abstract[18]	new[18]	_	_
4-23	328-330	in	abstract[18]	new[18]	_	_
4-24	331-334	the	abstract[18]|abstract[19]	new[18]|new[19]	coref	17-14[126_19]
4-25	335-363	far-visible-to-near-infrared	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-26	364-369	range	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-27	370-371	,	_	_	_	_
4-28	372-375	and	_	_	_	_
4-29	376-385	molecular	substance[20]	new[20]	coref	5-10[0_20]
4-30	386-392	oxygen	substance[20]	new[20]	_	_
4-31	393-394	.	_	_	_	_

#Text=PS photoexcitation during PDT gives rise to cytotoxic reactive oxygen species ( ROS ) such as singlet oxygen ( 1O2 ) .
5-1	395-397	PS	abstract|abstract[22]	giv|new[22]	coref|coref	6-1[31_0]|6-1[31_0]
5-2	398-413	photoexcitation	abstract[22]	new[22]	_	_
5-3	414-420	during	abstract[22]	new[22]	_	_
5-4	421-424	PDT	abstract[22]|abstract	new[22]|giv	coref	6-9
5-5	425-430	gives	_	_	_	_
5-6	431-435	rise	event[24]	new[24]	_	_
5-7	436-438	to	event[24]	new[24]	_	_
5-8	439-448	cytotoxic	event[24]|animal[26]	new[24]|new[26]	_	_
5-9	449-457	reactive	event[24]|animal[26]	new[24]|new[26]	_	_
5-10	458-464	oxygen	event[24]|substance|animal[26]	new[24]|giv|new[26]	coref	5-17[29_0]
5-11	465-472	species	event[24]|animal[26]	new[24]|new[26]	_	_
5-12	473-474	(	_	_	_	_
5-13	475-478	ROS	substance	new	_	_
5-14	479-480	)	_	_	_	_
5-15	481-485	such	_	_	_	_
5-16	486-488	as	_	_	_	_
5-17	489-496	singlet	substance|substance[29]	new|giv[29]	appos|appos	5-20[0_29]|5-20[0_29]
5-18	497-503	oxygen	substance[29]	giv[29]	_	_
5-19	504-505	(	_	_	_	_
5-20	506-509	1O2	substance	giv	coref	16-27
5-21	510-511	)	_	_	_	_
5-22	512-513	.	_	_	_	_

#Text=The first PS to receive FDA approval for PDT applications was Photofrin® , an oligomeric form of hematoporphyrin that continues to be used for a variety of malignancies .
6-1	514-517	The	abstract[31]	giv[31]	coref	6-12[0_31]
6-2	518-523	first	abstract[31]	giv[31]	_	_
6-3	524-526	PS	abstract[31]	giv[31]	_	_
6-4	527-529	to	_	_	_	_
6-5	530-537	receive	_	_	_	_
6-6	538-541	FDA	event[32]	new[32]	_	_
6-7	542-550	approval	event[32]	new[32]	_	_
6-8	551-554	for	_	_	_	_
6-9	555-558	PDT	abstract|abstract[34]	giv|new[34]	coref|coref	7-8|7-8
6-10	559-571	applications	abstract[34]	new[34]	_	_
6-11	572-575	was	_	_	_	_
6-12	576-586	Photofrin®	abstract	giv	appos	6-14[36_0]
6-13	587-588	,	_	_	_	_
6-14	589-591	an	abstract[36]	giv[36]	coref	9-9[0_36]
6-15	592-602	oligomeric	abstract[36]	giv[36]	_	_
6-16	603-607	form	abstract[36]	giv[36]	_	_
6-17	608-610	of	abstract[36]	giv[36]	_	_
6-18	611-626	hematoporphyrin	abstract[36]|substance	giv[36]|new	_	_
6-19	627-631	that	_	_	_	_
6-20	632-641	continues	_	_	_	_
6-21	642-644	to	_	_	_	_
6-22	645-647	be	_	_	_	_
6-23	648-652	used	_	_	_	_
6-24	653-656	for	_	_	_	_
6-25	657-658	a	abstract[38]	new[38]	_	_
6-26	659-666	variety	abstract[38]	new[38]	_	_
6-27	667-669	of	abstract[38]	new[38]	_	_
6-28	670-682	malignancies	abstract[38]|abstract	new[38]|new	_	_
6-29	683-684	.	_	_	_	_

#Text=Unlike more conventional chemotherapy or radiotherapy , PDT has few ( if any ) light-independent side effects and is non-invasive and site-specific , i. e. , limited to the tumor upon which light is directed , typically via fiber optic networks .
7-1	685-691	Unlike	_	_	_	_
7-2	692-696	more	abstract[40]	new[40]	coref	13-13[0_40]
7-3	697-709	conventional	abstract[40]	new[40]	_	_
7-4	710-722	chemotherapy	abstract[40]	new[40]	_	_
7-5	723-725	or	_	_	_	_
7-6	726-738	radiotherapy	abstract	new	coref	13-11
7-7	739-740	,	_	_	_	_
7-8	741-744	PDT	abstract	giv	coref	8-3
7-9	745-748	has	_	_	_	_
7-10	749-752	few	_	_	_	_
7-11	753-754	(	_	_	_	_
7-12	755-757	if	_	_	_	_
7-13	758-761	any	abstract[44]	new[44]	coref	18-4[136_44]
7-14	762-763	)	abstract[44]	new[44]	_	_
7-15	764-781	light-independent	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-16	782-786	side	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-17	787-794	effects	abstract[44]	new[44]	_	_
7-18	795-798	and	abstract[44]	new[44]	_	_
7-19	799-801	is	abstract[44]	new[44]	_	_
7-20	802-814	non-invasive	abstract[44]	new[44]	_	_
7-21	815-818	and	abstract[44]	new[44]	_	_
7-22	819-832	site-specific	abstract[44]	new[44]	_	_
7-23	833-834	,	abstract[44]	new[44]	_	_
7-24	835-837	i.	abstract[44]	new[44]	_	_
7-25	838-840	e.	abstract[44]	new[44]	_	_
7-26	841-842	,	_	_	_	_
7-27	843-850	limited	_	_	_	_
7-28	851-853	to	_	_	_	_
7-29	854-857	the	abstract[45]	new[45]	coref	12-36[0_45]
7-30	858-863	tumor	abstract[45]	new[45]	_	_
7-31	864-868	upon	_	_	_	_
7-32	869-874	which	_	_	_	_
7-33	875-880	light	abstract	giv	_	_
7-34	881-883	is	_	_	_	_
7-35	884-892	directed	_	_	_	_
7-36	893-894	,	_	_	_	_
7-37	895-904	typically	place[49]	new[49]	_	_
7-38	905-908	via	place[49]	new[49]	_	_
7-39	909-914	fiber	substance|place[49]	new|new[49]	_	_
7-40	915-920	optic	substance|place[49]	new|new[49]	_	_
7-41	921-929	networks	place[49]	new[49]	_	_
7-42	930-931	.	_	_	_	_

#Text=Moreover , PDT can often overcome the innate or acquired resistance to other therapies that many tumors exhibit .
8-1	932-940	Moreover	_	_	_	_
8-2	941-942	,	_	_	_	_
8-3	943-946	PDT	abstract	giv	coref	12-7
8-4	947-950	can	_	_	_	_
8-5	951-956	often	_	_	_	_
8-6	957-965	overcome	_	_	_	_
8-7	966-969	the	abstract[51]	new[51]	coref	13-8[90_51]
8-8	970-976	innate	abstract[51]	new[51]	_	_
8-9	977-979	or	abstract[51]	new[51]	_	_
8-10	980-988	acquired	abstract[51]	new[51]	_	_
8-11	989-999	resistance	abstract[51]	new[51]	_	_
8-12	1000-1002	to	abstract[51]	new[51]	_	_
8-13	1003-1008	other	abstract[51]|abstract[52]	new[51]|new[52]	_	_
8-14	1009-1018	therapies	abstract[51]|abstract[52]	new[51]|new[52]	_	_
8-15	1019-1023	that	_	_	_	_
8-16	1024-1028	many	object[53]	giv[53]	_	_
8-17	1029-1035	tumors	object[53]	giv[53]	_	_
8-18	1036-1043	exhibit	_	_	_	_
8-19	1044-1045	.	_	_	_	_

#Text=In addition to pre-existing administered sensitizers such as Photofrin® , pro-sensitizers have been developed , one common example being 5-aminolevulinic acid ( ALA ) .
9-1	1046-1048	In	_	_	_	_
9-2	1049-1057	addition	_	_	_	_
9-3	1058-1060	to	_	_	_	_
9-4	1061-1073	pre-existing	substance[54]	new[54]	_	_
9-5	1074-1086	administered	substance[54]	new[54]	_	_
9-6	1087-1098	sensitizers	substance[54]	new[54]	_	_
9-7	1099-1103	such	substance[54]	new[54]	_	_
9-8	1104-1106	as	substance[54]	new[54]	_	_
9-9	1107-1117	Photofrin®	substance[54]|abstract	new[54]|giv	coref	10-21[68_0]
9-10	1118-1119	,	_	_	_	_
9-11	1120-1135	pro-sensitizers	substance	new	_	_
9-12	1136-1140	have	_	_	_	_
9-13	1141-1145	been	_	_	_	_
9-14	1146-1155	developed	_	_	_	_
9-15	1156-1157	,	_	_	_	_
9-16	1158-1161	one	substance[57]	new[57]	coref	9-20[58_57]
9-17	1162-1168	common	substance[57]	new[57]	_	_
9-18	1169-1176	example	substance[57]	new[57]	_	_
9-19	1177-1182	being	_	_	_	_
9-20	1183-1199	5-aminolevulinic	substance[58]	giv[58]	coref	10-8[0_58]
9-21	1200-1204	acid	substance[58]	giv[58]	_	_
9-22	1205-1206	(	_	_	_	_
9-23	1207-1210	ALA	place	new	coref	10-11
9-24	1211-1212	)	_	_	_	_
9-25	1213-1214	.	_	_	_	_

#Text=Upon entering cancer cells via an amino acid transporter , ALA is metabolized to protoporphyrin IX ( PpIX ) , the active PS , via the heme biosynthetic pathway , PpIX accumulating initially in mitochondria .
10-1	1215-1219	Upon	_	_	_	_
10-2	1220-1228	entering	_	_	_	_
10-3	1229-1235	cancer	abstract|object[61]	new|new[61]	coref|coref|coref|coref	11-6[75_61]|13-2|11-6[75_61]|13-2
10-4	1236-1241	cells	object[61]	new[61]	_	_
10-5	1242-1245	via	_	_	_	_
10-6	1246-1248	an	abstract[63]	new[63]	coref	14-15[101_63]
10-7	1249-1254	amino	abstract[63]	new[63]	_	_
10-8	1255-1259	acid	substance|abstract[63]	giv|new[63]	_	_
10-9	1260-1271	transporter	abstract[63]	new[63]	_	_
10-10	1272-1273	,	_	_	_	_
10-11	1274-1277	ALA	place	giv	coref	12-19
10-12	1278-1280	is	_	_	_	_
10-13	1281-1292	metabolized	_	_	_	_
10-14	1293-1295	to	_	_	_	_
10-15	1296-1310	protoporphyrin	person|quantity[66]	new|new[66]	_	_
10-16	1311-1313	IX	quantity[66]	new[66]	_	_
10-17	1314-1315	(	_	_	_	_
10-18	1316-1320	PpIX	object	new	coref	10-31
10-19	1321-1322	)	_	_	_	_
10-20	1323-1324	,	_	_	_	_
10-21	1325-1328	the	abstract[68]	giv[68]	coref	23-13[0_68]
10-22	1329-1335	active	abstract[68]	giv[68]	_	_
10-23	1336-1338	PS	abstract[68]	giv[68]	_	_
10-24	1339-1340	,	abstract[68]	giv[68]	_	_
10-25	1341-1344	via	abstract[68]	giv[68]	_	_
10-26	1345-1348	the	abstract[68]|abstract[71]	giv[68]|new[71]	_	_
10-27	1349-1353	heme	abstract[68]|abstract|abstract[71]	giv[68]|new|new[71]	coref	11-12
10-28	1354-1366	biosynthetic	abstract[68]|abstract|abstract[71]	giv[68]|new|new[71]	_	_
10-29	1367-1374	pathway	abstract[68]|abstract[71]	giv[68]|new[71]	_	_
10-30	1375-1376	,	_	_	_	_
10-31	1377-1381	PpIX	substance	giv	coref	14-11[99_0]
10-32	1382-1394	accumulating	_	_	_	_
10-33	1395-1404	initially	_	_	_	_
10-34	1405-1407	in	_	_	_	_
10-35	1408-1420	mitochondria	place	new	_	_
10-36	1421-1422	.	_	_	_	_

#Text=For rapid proliferative needs , tumor cells are more active in heme synthesis than normal counterparts .
11-1	1423-1426	For	_	_	_	_
11-2	1427-1432	rapid	abstract[74]	new[74]	_	_
11-3	1433-1446	proliferative	abstract[74]	new[74]	_	_
11-4	1447-1452	needs	abstract[74]	new[74]	_	_
11-5	1453-1454	,	_	_	_	_
11-6	1455-1460	tumor	object[75]	giv[75]	coref	13-1[88_75]
11-7	1461-1466	cells	object[75]	giv[75]	_	_
11-8	1467-1470	are	_	_	_	_
11-9	1471-1475	more	_	_	_	_
11-10	1476-1482	active	_	_	_	_
11-11	1483-1485	in	_	_	_	_
11-12	1486-1490	heme	abstract|abstract[77]	giv|new[77]	_	_
11-13	1491-1500	synthesis	abstract[77]	new[77]	_	_
11-14	1501-1505	than	abstract[77]	new[77]	_	_
11-15	1506-1512	normal	abstract[77]|abstract[78]	new[77]|new[78]	_	_
11-16	1513-1525	counterparts	abstract[77]|abstract[78]	new[77]|new[78]	_	_
11-17	1526-1527	.	_	_	_	_

#Text=In addition to acting as a PDT sensitizer , ALA-induced PpIX , like that induced by more lipophilic ALA esters , e. g. , Hexvix , can serve as a highly effective fluorophore for image-guided tumor resection .
12-1	1528-1530	In	_	_	_	_
12-2	1531-1539	addition	_	_	_	_
12-3	1540-1542	to	_	_	_	_
12-4	1543-1549	acting	_	_	_	_
12-5	1550-1552	as	_	_	_	_
12-6	1553-1554	a	_	_	_	_
12-7	1555-1558	PDT	abstract	giv	coref	13-18
12-8	1559-1569	sensitizer	_	_	_	_
12-9	1570-1571	,	_	_	_	_
12-10	1572-1583	ALA-induced	object[80]	new[80]	coref	19-25[151_80]
12-11	1584-1588	PpIX	object[80]	new[80]	_	_
12-12	1589-1590	,	_	_	_	_
12-13	1591-1595	like	_	_	_	_
12-14	1596-1600	that	_	_	_	_
12-15	1601-1608	induced	_	_	_	_
12-16	1609-1611	by	_	_	_	_
12-17	1612-1616	more	abstract[82]	new[82]	appos	12-22[83_82]
12-18	1617-1627	lipophilic	abstract[82]	new[82]	_	_
12-19	1628-1631	ALA	place|abstract[82]	giv|new[82]	_	_
12-20	1632-1638	esters	abstract[82]	new[82]	_	_
12-21	1639-1640	,	_	_	_	_
12-22	1641-1643	e.	object[83]	giv[83]	appos	12-25[0_83]
12-23	1644-1646	g.	object[83]	giv[83]	_	_
12-24	1647-1648	,	_	_	_	_
12-25	1649-1655	Hexvix	object	giv	coref	16-41[118_0]
12-26	1656-1657	,	_	_	_	_
12-27	1658-1661	can	_	_	_	_
12-28	1662-1667	serve	_	_	_	_
12-29	1668-1670	as	_	_	_	_
12-30	1671-1672	a	_	_	_	_
12-31	1673-1679	highly	_	_	_	_
12-32	1680-1689	effective	_	_	_	_
12-33	1690-1701	fluorophore	_	_	_	_
12-34	1702-1705	for	_	_	_	_
12-35	1706-1718	image-guided	event[86]	new[86]	_	_
12-36	1719-1724	tumor	abstract|event[86]	giv|new[86]	coref	23-2[175_0]
12-37	1725-1734	resection	event[86]	new[86]	_	_
12-38	1735-1736	.	_	_	_	_

#Text=Many cancer cells exhibit an intrinsic or acquired resistance to radiotherapy or chemotherapy , and resistance to PDT has also been demonstrated .
13-1	1737-1741	Many	object[88]	giv[88]	coref	16-39[117_88]
13-2	1742-1748	cancer	abstract|object[88]	giv|giv[88]	coref	17-38
13-3	1749-1754	cells	object[88]	giv[88]	_	_
13-4	1755-1762	exhibit	_	_	_	_
13-5	1763-1765	an	abstract[89]	new[89]	_	_
13-6	1766-1775	intrinsic	abstract[89]	new[89]	_	_
13-7	1776-1778	or	_	_	_	_
13-8	1779-1787	acquired	abstract[90]	giv[90]	coref	13-16[93_90]
13-9	1788-1798	resistance	abstract[90]	giv[90]	_	_
13-10	1799-1801	to	abstract[90]	giv[90]	_	_
13-11	1802-1814	radiotherapy	abstract[90]|abstract	giv[90]|giv	_	_
13-12	1815-1817	or	abstract[90]	giv[90]	_	_
13-13	1818-1830	chemotherapy	abstract[90]|abstract	giv[90]|giv	_	_
13-14	1831-1832	,	_	_	_	_
13-15	1833-1836	and	_	_	_	_
13-16	1837-1847	resistance	abstract[93]	giv[93]	coref	14-6[0_93]
13-17	1848-1850	to	abstract[93]	giv[93]	_	_
13-18	1851-1854	PDT	abstract[93]|abstract	giv[93]|giv	coref	24-23
13-19	1855-1858	has	_	_	_	_
13-20	1859-1863	also	_	_	_	_
13-21	1864-1868	been	_	_	_	_
13-22	1869-1881	demonstrated	_	_	_	_
13-23	1882-1883	.	_	_	_	_

#Text=For ALA-PDT , one notable resistance mechanism involves efflux of newly synthesized PpIX via the plasma membrane transporter ABCG2 .
14-1	1884-1887	For	_	_	_	_
14-2	1888-1895	ALA-PDT	substance	new	_	_
14-3	1896-1897	,	_	_	_	_
14-4	1898-1901	one	abstract[97]	new[97]	coref	15-1[102_97]
14-5	1902-1909	notable	abstract[97]	new[97]	_	_
14-6	1910-1920	resistance	abstract|abstract[97]	giv|new[97]	coref	17-33[132_0]
14-7	1921-1930	mechanism	abstract[97]	new[97]	_	_
14-8	1931-1939	involves	_	_	_	_
14-9	1940-1946	efflux	event[98]	new[98]	_	_
14-10	1947-1949	of	event[98]	new[98]	_	_
14-11	1950-1955	newly	event[98]|object[99]	new[98]|giv[99]	_	_
14-12	1956-1967	synthesized	event[98]|object[99]	new[98]|giv[99]	_	_
14-13	1968-1972	PpIX	event[98]|object[99]	new[98]|giv[99]	_	_
14-14	1973-1976	via	event[98]|object[99]	new[98]|giv[99]	_	_
14-15	1977-1980	the	event[98]|object[99]|abstract[101]	new[98]|giv[99]|giv[101]	_	_
14-16	1981-1987	plasma	event[98]|object[99]|abstract[101]	new[98]|giv[99]|giv[101]	_	_
14-17	1988-1996	membrane	event[98]|object[99]|animal|abstract[101]	new[98]|giv[99]|new|giv[101]	_	_
14-18	1997-2008	transporter	event[98]|object[99]|abstract[101]	new[98]|giv[99]|giv[101]	_	_
14-19	2009-2014	ABCG2	event[98]|object[99]|abstract[101]	new[98]|giv[99]|giv[101]	_	_
14-20	2015-2016	.	_	_	_	_

#Text=Another important mechanism involves nitric oxide ( NO ) generated by constitutive and/or PDT stress-upregulated inducible nitric oxide synthase ( iNOS/NOS2 ) .
15-1	2017-2024	Another	abstract[102]	giv[102]	_	_
15-2	2025-2034	important	abstract[102]	giv[102]	_	_
15-3	2035-2044	mechanism	abstract[102]	giv[102]	_	_
15-4	2045-2053	involves	_	_	_	_
15-5	2054-2060	nitric	abstract|substance[104]	new|new[104]	coref|coref|coref|coref	15-17|15-18[0_104]|15-17|15-18[0_104]
15-6	2061-2066	oxide	substance[104]	new[104]	_	_
15-7	2067-2068	(	_	_	_	_
15-8	2069-2071	NO	_	_	_	_
15-9	2072-2073	)	_	_	_	_
15-10	2074-2083	generated	_	_	_	_
15-11	2084-2086	by	_	_	_	_
15-12	2087-2099	constitutive	_	_	_	_
15-13	2100-2106	and/or	_	_	_	_
15-14	2107-2110	PDT	_	_	_	_
15-15	2111-2129	stress-upregulated	_	_	_	_
15-16	2130-2139	inducible	_	_	_	_
15-17	2140-2146	nitric	abstract	giv	_	_
15-18	2147-2152	oxide	substance	giv	_	_
15-19	2153-2161	synthase	_	_	_	_
15-20	2162-2163	(	_	_	_	_
15-21	2164-2173	iNOS/NOS2	place	new	_	_
15-22	2174-2175	)	_	_	_	_
15-23	2176-2177	.	_	_	_	_

#Text=NO is a bioactive free radical molecule ( 1 – 2 sec lifetime in water ) that diffuses freely on its own and , similar to oxygen ( O2 ) , tends to partition into hydrophobic regions of cells , e. g. , cell membranes .
16-1	2178-2180	NO	_	_	_	_
16-2	2181-2183	is	_	_	_	_
16-3	2184-2185	a	substance[108]	new[108]	_	_
16-4	2186-2195	bioactive	substance[108]	new[108]	_	_
16-5	2196-2200	free	substance[108]	new[108]	_	_
16-6	2201-2208	radical	substance[108]	new[108]	_	_
16-7	2209-2217	molecule	substance[108]	new[108]	_	_
16-8	2218-2219	(	_	_	_	_
16-9	2220-2221	1	abstract[111]	new[111]	_	_
16-10	2222-2223	–	abstract[111]	new[111]	_	_
16-11	2224-2225	2	quantity|abstract[111]	new|new[111]	_	_
16-12	2226-2229	sec	person|abstract[111]	new|new[111]	_	_
16-13	2230-2238	lifetime	abstract[111]	new[111]	_	_
16-14	2239-2241	in	abstract[111]	new[111]	_	_
16-15	2242-2247	water	abstract[111]|substance	new[111]|new	ana	16-21
16-16	2248-2249	)	_	_	_	_
16-17	2250-2254	that	_	_	_	_
16-18	2255-2263	diffuses	_	_	_	_
16-19	2264-2270	freely	_	_	_	_
16-20	2271-2273	on	_	_	_	_
16-21	2274-2277	its	substance	giv	_	_
16-22	2278-2281	own	_	_	_	_
16-23	2282-2285	and	_	_	_	_
16-24	2286-2287	,	_	_	_	_
16-25	2288-2295	similar	_	_	_	_
16-26	2296-2298	to	_	_	_	_
16-27	2299-2305	oxygen	substance	giv	appos	16-29
16-28	2306-2307	(	_	_	_	_
16-29	2308-2310	O2	substance	giv	_	_
16-30	2311-2312	)	_	_	_	_
16-31	2313-2314	,	_	_	_	_
16-32	2315-2320	tends	_	_	_	_
16-33	2321-2323	to	_	_	_	_
16-34	2324-2333	partition	_	_	_	_
16-35	2334-2338	into	_	_	_	_
16-36	2339-2350	hydrophobic	place[116]	new[116]	_	_
16-37	2351-2358	regions	place[116]	new[116]	_	_
16-38	2359-2361	of	place[116]	new[116]	_	_
16-39	2362-2367	cells	place[116]|object[117]	new[116]|giv[117]	coref	17-36[134_117]
16-40	2368-2369	,	place[116]|object[117]	new[116]|giv[117]	_	_
16-41	2370-2372	e.	place[116]|object[117]|place[118]	new[116]|giv[117]|giv[118]	coref	17-9[0_118]
16-42	2373-2375	g.	place[116]|object[117]|place[118]	new[116]|giv[117]|giv[118]	_	_
16-43	2376-2377	,	place[116]|object[117]	new[116]|giv[117]	_	_
16-44	2378-2382	cell	place[116]|object[117]|place|place[120]	new[116]|giv[117]|new|new[120]	coref|coref	19-10|19-10
16-45	2383-2392	membranes	place[116]|object[117]|place[120]	new[116]|giv[117]|new[120]	_	_
16-46	2393-2394	.	_	_	_	_

#Text=At relatively low steady state levels ( e. g. , 50 – 300 nM range ) , NO is known to play a key signaling role in survival , migration , and drug resistance of many different cancer cells .
17-1	2395-2397	At	_	_	_	_
17-2	2398-2408	relatively	abstract[122]	new[122]	_	_
17-3	2409-2412	low	abstract[122]	new[122]	_	_
17-4	2413-2419	steady	abstract[122]	new[122]	_	_
17-5	2420-2425	state	abstract|abstract[122]	new|new[122]	_	_
17-6	2426-2432	levels	abstract[122]	new[122]	_	_
17-7	2433-2434	(	_	_	_	_
17-8	2435-2437	e.	_	_	_	_
17-9	2438-2440	g.	place	giv	coref	18-26[141_0]
17-10	2441-2442	,	_	_	_	_
17-11	2443-2445	50	_	_	_	_
17-12	2446-2447	–	_	_	_	_
17-13	2448-2451	300	quantity	new	_	_
17-14	2452-2454	nM	quantity|abstract[126]	new|giv[126]	_	_
17-15	2455-2460	range	abstract[126]	giv[126]	_	_
17-16	2461-2462	)	_	_	_	_
17-17	2463-2464	,	_	_	_	_
17-18	2465-2467	NO	_	_	_	_
17-19	2468-2470	is	_	_	_	_
17-20	2471-2476	known	_	_	_	_
17-21	2477-2479	to	_	_	_	_
17-22	2480-2484	play	_	_	_	_
17-23	2485-2486	a	abstract[128]	new[128]	_	_
17-24	2487-2490	key	abstract[128]	new[128]	_	_
17-25	2491-2500	signaling	abstract|abstract[128]	new|new[128]	_	_
17-26	2501-2505	role	abstract[128]	new[128]	_	_
17-27	2506-2508	in	abstract[128]	new[128]	_	_
17-28	2509-2517	survival	abstract[128]|event	new[128]|new	_	_
17-29	2518-2519	,	abstract[128]	new[128]	_	_
17-30	2520-2529	migration	abstract[128]|event	new[128]|new	_	_
17-31	2530-2531	,	abstract[128]	new[128]	_	_
17-32	2532-2535	and	abstract[128]	new[128]	_	_
17-33	2536-2540	drug	abstract[128]|substance|abstract[132]	new[128]|new|giv[132]	ana|ana	18-1[0_132]|18-1[0_132]
17-34	2541-2551	resistance	abstract[128]|abstract[132]	new[128]|giv[132]	_	_
17-35	2552-2554	of	abstract[128]|abstract[132]	new[128]|giv[132]	_	_
17-36	2555-2559	many	abstract[128]|abstract[132]|object[134]	new[128]|giv[132]|giv[134]	coref	20-10[0_134]
17-37	2560-2569	different	abstract[128]|abstract[132]|object[134]	new[128]|giv[132]|giv[134]	_	_
17-38	2570-2576	cancer	abstract[128]|abstract[132]|abstract|object[134]	new[128]|giv[132]|giv|giv[134]	coref	19-9
17-39	2577-2582	cells	abstract[128]|abstract[132]|object[134]	new[128]|giv[132]|giv[134]	_	_
17-40	2583-2584	.	_	_	_	_

#Text=This contrasts with the cytotoxic effects of NO produced at much higher levels ( ≥1 µM ) by activated macrophages during an inflammatory response , e. g. , to infection .
18-1	2585-2589	This	abstract	giv	_	_
18-2	2590-2599	contrasts	_	_	_	_
18-3	2600-2604	with	_	_	_	_
18-4	2605-2608	the	abstract[136]	giv[136]	coref	24-11[188_136]
18-5	2609-2618	cytotoxic	abstract[136]	giv[136]	_	_
18-6	2619-2626	effects	abstract[136]	giv[136]	_	_
18-7	2627-2629	of	_	_	_	_
18-8	2630-2632	NO	_	_	_	_
18-9	2633-2641	produced	_	_	_	_
18-10	2642-2644	at	_	_	_	_
18-11	2645-2649	much	quantity[137]	new[137]	appos	18-15[138_137]
18-12	2650-2656	higher	quantity[137]	new[137]	_	_
18-13	2657-2663	levels	quantity[137]	new[137]	_	_
18-14	2664-2665	(	_	_	_	_
18-15	2666-2668	≥1	quantity[138]	giv[138]	_	_
18-16	2669-2671	µM	quantity[138]	giv[138]	_	_
18-17	2672-2673	)	_	_	_	_
18-18	2674-2676	by	_	_	_	_
18-19	2677-2686	activated	substance[139]	new[139]	_	_
18-20	2687-2698	macrophages	substance[139]	new[139]	_	_
18-21	2699-2705	during	substance[139]	new[139]	_	_
18-22	2706-2708	an	substance[139]|abstract[140]	new[139]|new[140]	coref	22-12[173_140]
18-23	2709-2721	inflammatory	substance[139]|abstract[140]	new[139]|new[140]	_	_
18-24	2722-2730	response	substance[139]|abstract[140]	new[139]|new[140]	_	_
18-25	2731-2732	,	_	_	_	_
18-26	2733-2735	e.	abstract[141]	giv[141]	_	_
18-27	2736-2738	g.	abstract[141]	giv[141]	_	_
18-28	2739-2740	,	_	_	_	_
18-29	2741-2743	to	_	_	_	_
18-30	2744-2753	infection	event	new	_	_
18-31	2754-2755	.	_	_	_	_

#Text=In previous work , we discovered that various cancer cell lines significantly upregulate cytoprotective iNOS and NO after a moderate photodynamic challenge sensitized by ALA-induced PpIX .
19-1	2756-2758	In	_	_	_	_
19-2	2759-2767	previous	abstract[143]	new[143]	_	_
19-3	2768-2772	work	abstract[143]	new[143]	_	_
19-4	2773-2774	,	_	_	_	_
19-5	2775-2777	we	person	acc	ana	22-1
19-6	2778-2788	discovered	_	_	_	_
19-7	2789-2793	that	_	_	_	_
19-8	2794-2801	various	abstract[147]	new[147]	coref	25-11[197_147]
19-9	2802-2808	cancer	abstract|abstract[147]	giv|new[147]	coref	24-2[183_0]
19-10	2809-2813	cell	place|abstract[147]	giv|new[147]	_	_
19-11	2814-2819	lines	abstract[147]	new[147]	_	_
19-12	2820-2833	significantly	_	_	_	_
19-13	2834-2844	upregulate	_	_	_	_
19-14	2845-2859	cytoprotective	abstract[148]	new[148]	coref	21-27[0_148]
19-15	2860-2864	iNOS	abstract[148]	new[148]	_	_
19-16	2865-2868	and	_	_	_	_
19-17	2869-2871	NO	_	_	_	_
19-18	2872-2877	after	_	_	_	_
19-19	2878-2879	a	event[150]	new[150]	_	_
19-20	2880-2888	moderate	event[150]	new[150]	_	_
19-21	2889-2901	photodynamic	substance|event[150]	giv|new[150]	_	_
19-22	2902-2911	challenge	event[150]	new[150]	_	_
19-23	2912-2922	sensitized	_	_	_	_
19-24	2923-2925	by	_	_	_	_
19-25	2926-2937	ALA-induced	abstract[151]	giv[151]	_	_
19-26	2938-2942	PpIX	abstract[151]	giv[151]	_	_
19-27	2943-2944	.	_	_	_	_

#Text=The iNOS/NO induction in PDT-surviving ( still attached ) cells was relatively rapid after irradiation ( 2 – 3 h ) and prolonged ( at least 24 h ) .
20-1	2945-2948	The	event[153]	new[153]	_	_
20-2	2949-2956	iNOS/NO	place|event[153]	new|new[153]	_	_
20-3	2957-2966	induction	event[153]	new[153]	_	_
20-4	2967-2969	in	event[153]	new[153]	_	_
20-5	2970-2983	PDT-surviving	event[153]|place	new[153]|new	_	_
20-6	2984-2985	(	_	_	_	_
20-7	2986-2991	still	_	_	_	_
20-8	2992-3000	attached	_	_	_	_
20-9	3001-3002	)	_	_	_	_
20-10	3003-3008	cells	object	giv	coref	21-3[160_0]
20-11	3009-3012	was	_	_	_	_
20-12	3013-3023	relatively	_	_	_	_
20-13	3024-3029	rapid	_	_	_	_
20-14	3030-3035	after	_	_	_	_
20-15	3036-3047	irradiation	abstract[156]	new[156]	_	_
20-16	3048-3049	(	abstract[156]	new[156]	_	_
20-17	3050-3051	2	abstract[156]	new[156]	_	_
20-18	3052-3053	–	abstract[156]	new[156]	_	_
20-19	3054-3055	3	abstract[156]|quantity	new[156]|new	_	_
20-20	3056-3057	h	abstract[156]|quantity	new[156]|new	coref	20-26[159_0]
20-21	3058-3059	)	abstract[156]	new[156]	_	_
20-22	3060-3063	and	_	_	_	_
20-23	3064-3073	prolonged	_	_	_	_
20-24	3074-3075	(	_	_	_	_
20-25	3076-3078	at	_	_	_	_
20-26	3079-3084	least	quantity[159]	giv[159]	_	_
20-27	3085-3087	24	quantity[159]	giv[159]	_	_
20-28	3088-3089	h	quantity[159]	giv[159]	_	_
20-29	3090-3091	)	_	_	_	_
20-30	3092-3093	.	_	_	_	_

#Text=Importantly , these cells exhibited a more aggressive growth , migratory , and invasive phenotype than non-photostressed controls , and this was suppressed by inhibition of iNOS or by NO scavenging .
21-1	3094-3105	Importantly	_	_	_	_
21-2	3106-3107	,	_	_	_	_
21-3	3108-3113	these	object[160]	giv[160]	coref	22-6[171_160]
21-4	3114-3119	cells	object[160]	giv[160]	_	_
21-5	3120-3129	exhibited	_	_	_	_
21-6	3130-3131	a	abstract[161]	new[161]	_	_
21-7	3132-3136	more	abstract[161]	new[161]	_	_
21-8	3137-3147	aggressive	abstract[161]	new[161]	_	_
21-9	3148-3154	growth	abstract[161]	new[161]	_	_
21-10	3155-3156	,	_	_	_	_
21-11	3157-3166	migratory	_	_	_	_
21-12	3167-3168	,	_	_	_	_
21-13	3169-3172	and	_	_	_	_
21-14	3173-3181	invasive	abstract[162]	new[162]	ana	21-21[0_162]
21-15	3182-3191	phenotype	abstract[162]	new[162]	_	_
21-16	3192-3196	than	abstract[162]	new[162]	_	_
21-17	3197-3214	non-photostressed	abstract[162]|event[163]	new[162]|new[163]	_	_
21-18	3215-3223	controls	abstract[162]|event[163]	new[162]|new[163]	_	_
21-19	3224-3225	,	_	_	_	_
21-20	3226-3229	and	_	_	_	_
21-21	3230-3234	this	abstract	giv	_	_
21-22	3235-3238	was	_	_	_	_
21-23	3239-3249	suppressed	_	_	_	_
21-24	3250-3252	by	_	_	_	_
21-25	3253-3263	inhibition	abstract[165]	new[165]	_	_
21-26	3264-3266	of	abstract[165]	new[165]	_	_
21-27	3267-3271	iNOS	abstract[165]|abstract	new[165]|giv	_	_
21-28	3272-3274	or	_	_	_	_
21-29	3275-3277	by	_	_	_	_
21-30	3278-3280	NO	abstract[167]	new[167]	_	_
21-31	3281-3291	scavenging	abstract[167]	new[167]	_	_
21-32	3292-3293	.	_	_	_	_

#Text=We postulated that induced diffusible NO from PDT-targeted cells might elicit a pro-growth/migratory response in non- or minimally-targeted bystander cells .
22-1	3294-3296	We	person	giv	ana	24-8
22-2	3297-3307	postulated	_	_	_	_
22-3	3308-3312	that	_	_	_	_
22-4	3313-3320	induced	_	_	_	_
22-5	3321-3331	diffusible	person	new	_	_
22-6	3332-3334	NO	object[171]	giv[171]	coref	22-16[174_171]
22-7	3335-3339	from	object[171]	giv[171]	_	_
22-8	3340-3352	PDT-targeted	object|object[171]	new|giv[171]	_	_
22-9	3353-3358	cells	object[171]	giv[171]	_	_
22-10	3359-3364	might	_	_	_	_
22-11	3365-3371	elicit	_	_	_	_
22-12	3372-3373	a	abstract[173]	giv[173]	_	_
22-13	3374-3394	pro-growth/migratory	place|abstract[173]	new|giv[173]	_	_
22-14	3395-3403	response	abstract[173]	giv[173]	_	_
22-15	3404-3406	in	abstract[173]	giv[173]	_	_
22-16	3407-3411	non-	abstract[173]|object[174]	giv[173]|giv[174]	coref	24-5[185_174]
22-17	3412-3414	or	abstract[173]|object[174]	giv[173]|giv[174]	_	_
22-18	3415-3433	minimally-targeted	abstract[173]|object[174]	giv[173]|giv[174]	_	_
22-19	3434-3443	bystander	abstract[173]|object[174]	giv[173]|giv[174]	_	_
22-20	3444-3449	cells	abstract[173]|object[174]	giv[173]|giv[174]	_	_
22-21	3450-3451	.	_	_	_	_

#Text=In an actual tumor , such targeting diversity might result from uneven PS distribution due to irregularities in the tumor microvasculature .
23-1	3452-3454	In	_	_	_	_
23-2	3455-3457	an	abstract[175]	giv[175]	coref	23-20[0_175]
23-3	3458-3464	actual	abstract[175]	giv[175]	_	_
23-4	3465-3470	tumor	abstract[175]	giv[175]	_	_
23-5	3471-3472	,	_	_	_	_
23-6	3473-3477	such	abstract[176]	new[176]	_	_
23-7	3478-3487	targeting	abstract[176]	new[176]	_	_
23-8	3488-3497	diversity	abstract[176]	new[176]	_	_
23-9	3498-3503	might	_	_	_	_
23-10	3504-3510	result	_	_	_	_
23-11	3511-3515	from	_	_	_	_
23-12	3516-3522	uneven	abstract[178]	new[178]	_	_
23-13	3523-3525	PS	abstract|abstract[178]	giv|new[178]	_	_
23-14	3526-3538	distribution	abstract[178]	new[178]	_	_
23-15	3539-3542	due	_	_	_	_
23-16	3543-3545	to	_	_	_	_
23-17	3546-3560	irregularities	abstract[179]	new[179]	_	_
23-18	3561-3563	in	abstract[179]	new[179]	_	_
23-19	3564-3567	the	abstract[179]|object[181]	new[179]|new[181]	_	_
23-20	3568-3573	tumor	abstract[179]|abstract|object[181]	new[179]|giv|new[181]	_	_
23-21	3574-3590	microvasculature	abstract[179]|object[181]	new[179]|new[181]	_	_
23-22	3591-3592	.	_	_	_	_

#Text=Using photosensitized prostate cancer PC3 cells , we recently observed NO-mediated hyper-aggressive bystander effects for the first time in the context of PDT .
24-1	3593-3598	Using	_	_	_	_
24-2	3599-3614	photosensitized	abstract[183]	giv[183]	coref	25-13[0_183]
24-3	3615-3623	prostate	place|abstract[183]	new|giv[183]	coref	25-26
24-4	3624-3630	cancer	abstract[183]	giv[183]	_	_
24-5	3631-3634	PC3	substance|object[185]	new|giv[185]	coref|coref	25-26[205_0]|25-26[205_0]
24-6	3635-3640	cells	object[185]	giv[185]	_	_
24-7	3641-3642	,	_	_	_	_
24-8	3643-3645	we	person	giv	ana	25-6
24-9	3646-3654	recently	_	_	_	_
24-10	3655-3663	observed	_	_	_	_
24-11	3664-3675	NO-mediated	abstract[188]	giv[188]	_	_
24-12	3676-3692	hyper-aggressive	abstract[188]	giv[188]	_	_
24-13	3693-3702	bystander	person|abstract[188]	new|giv[188]	_	_
24-14	3703-3710	effects	abstract[188]	giv[188]	_	_
24-15	3711-3714	for	abstract[188]	giv[188]	_	_
24-16	3715-3718	the	abstract[188]|time[189]	giv[188]|new[189]	_	_
24-17	3719-3724	first	abstract[188]|time[189]	giv[188]|new[189]	_	_
24-18	3725-3729	time	abstract[188]|time[189]	giv[188]|new[189]	_	_
24-19	3730-3732	in	abstract[188]|time[189]	giv[188]|new[189]	_	_
24-20	3733-3736	the	abstract[188]|time[189]|abstract[190]	giv[188]|new[189]|new[190]	_	_
24-21	3737-3744	context	abstract[188]|time[189]|abstract[190]	giv[188]|new[189]|new[190]	_	_
24-22	3745-3747	of	abstract[188]|time[189]|abstract[190]	giv[188]|new[189]|new[190]	_	_
24-23	3748-3751	PDT	abstract[188]|time[189]|abstract[190]|event	giv[188]|new[189]|new[190]|giv	_	_
24-24	3752-3753	.	_	_	_	_

#Text=In the present study , we compared the ability of four PDT-treated cancer lines ( melanoma BLM , glioblastoma U87 , breast MDA-MB-231 , and prostate PC3 ) to stimulate NO-dependent aggressiveness in bystander cells of the same type .
25-1	3754-3756	In	_	_	_	_
25-2	3757-3760	the	abstract[192]	new[192]	_	_
25-3	3761-3768	present	abstract[192]	new[192]	_	_
25-4	3769-3774	study	abstract[192]	new[192]	_	_
25-5	3775-3776	,	_	_	_	_
25-6	3777-3779	we	person	giv	_	_
25-7	3780-3788	compared	_	_	_	_
25-8	3789-3792	the	abstract[194]	new[194]	_	_
25-9	3793-3800	ability	abstract[194]	new[194]	_	_
25-10	3801-3803	of	abstract[194]	new[194]	_	_
25-11	3804-3808	four	abstract[194]|abstract[197]	new[194]|giv[197]	appos	25-16[200_197]
25-12	3809-3820	PDT-treated	abstract[194]|object|abstract[197]	new[194]|new|giv[197]	_	_
25-13	3821-3827	cancer	abstract[194]|abstract|abstract[197]	new[194]|giv|giv[197]	_	_
25-14	3828-3833	lines	abstract[194]|abstract[197]	new[194]|giv[197]	_	_
25-15	3834-3835	(	_	_	_	_
25-16	3836-3844	melanoma	abstract|object[199]|abstract[200]	new|new[199]|giv[200]	_	_
25-17	3845-3848	BLM	object[199]|abstract[200]	new[199]|giv[200]	_	_
25-18	3849-3850	,	abstract[200]	giv[200]	_	_
25-19	3851-3863	glioblastoma	abstract[200]|place[201]	giv[200]|new[201]	_	_
25-20	3864-3867	U87	abstract[200]|place[201]	giv[200]|new[201]	_	_
25-21	3868-3869	,	abstract[200]	giv[200]	_	_
25-22	3870-3876	breast	abstract[200]|place|object[203]	giv[200]|new|new[203]	_	_
25-23	3877-3887	MDA-MB-231	abstract[200]|object[203]	giv[200]|new[203]	_	_
25-24	3888-3889	,	abstract[200]	giv[200]	_	_
25-25	3890-3893	and	abstract[200]	giv[200]	_	_
25-26	3894-3902	prostate	abstract[200]|place|substance[205]	giv[200]|giv|giv[205]	_	_
25-27	3903-3906	PC3	abstract[200]|substance[205]	giv[200]|giv[205]	_	_
25-28	3907-3908	)	_	_	_	_
25-29	3909-3911	to	_	_	_	_
25-30	3912-3921	stimulate	_	_	_	_
25-31	3922-3934	NO-dependent	abstract[206]	new[206]	_	_
25-32	3935-3949	aggressiveness	abstract[206]	new[206]	_	_
25-33	3950-3952	in	abstract[206]	new[206]	_	_
25-34	3953-3962	bystander	abstract[206]|person[207]	new[206]|new[207]	_	_
25-35	3963-3968	cells	abstract[206]|person[207]	new[206]|new[207]	_	_
25-36	3969-3971	of	abstract[206]|person[207]	new[206]|new[207]	_	_
25-37	3972-3975	the	abstract[206]|person[207]|abstract[208]	new[206]|new[207]|new[208]	_	_
25-38	3976-3980	same	abstract[206]|person[207]|abstract[208]	new[206]|new[207]|new[208]	_	_
25-39	3981-3985	type	abstract[206]|person[207]|abstract[208]	new[206]|new[207]|new[208]	_	_
25-40	3986-3987	.	_	_	_	_
